Navigation Links
HIV Vaccine Strategy Expands Immune Responses
Date:3/15/2010

Mosaic vaccines show promise in reducing the spread of deadly virus

LOS ALAMOS, N.M., March 15 /PRNewswire-USNewswire/ -- Two teams of researchers—including Los Alamos National Laboratory theoretical biologists Bette Korber, Will Fischer, Sydeaka Watson, and James Szinger—have announced an HIV vaccination strategy that has been shown to expand the breadth and depth of immune responses in rhesus monkeys. Rhesus monkeys provide the best animal model currently available for testing HIV vaccines.

(Logo: http://www.newscom.com/cgi-bin/prnh/20100315/DC69335)

The research appeared in two back-to-back articles in Nature Medicine this week, and outlines a strategy, called "mosaic vaccines," for reducing the spread of HIV, the virus that causes AIDS.

HIV is an extremely variable virus. One of the most daunting challenges for developing an effective HIV vaccine is designing one that stimulates immune responses that will protect an individual from the highly diverse spectrum of strains of the circulating virus. The mosaic vaccine design uses computational methods developed at Los Alamos to create small sets of highly variable artificial viral proteins. These proteins, in combination, provide nearly optimal coverage of the diverse forms of HIV circulating in the world today.

In one of the two papers, Dr. Dan Barouch of Beth Israel Deaconess Medical Center at Harvard University reported very promising results when HIV mosaic vaccines were embedded in specialized vectors—organisms that transmit pathogens to a host—that were designed in his laboratory specifically to make strong "Killer T cell" responses. Killer T cells enable our immune system to recognize and kill virally infected cells, and they help clear or contain viral infections.

When this vaccine was used to immunize rhesus monkeys against HIV-1,  the most predominant and transmittable type of the virus, the researchers observed up to four-fold improvement in the monkeys' immune response to HIV-1, compared with natural vaccine strains similar to those that have been used in the past. In the other, complementary study, Drs. Norman Letvin and Sampa Santra, also affiliated with the Beth Israel Deaconess Medical Center, and Dr. Barton Haynes of Duke University, used a distinct HIV mosaic vaccine construct that stimulated an immune response emphasizing "Helper T cells"—the kinds of cells required to stimulate and control many aspects of an immune response. This study also showed an increased breadth and depth of anti-HIV immune responses to the vaccine. Both approaches demonstrated that mosaic vaccines improve the immune response against genetically diverse HIV-1 viruses.

"This research indicates that mosaic vaccines represent a promising strategy to expand coverage for genetically diverse pathogens such as HIV-1," Korber said. "The next step is to see whether the improved immune response found in Rhesus monkeys will hold up in humans, so small-scale human safety and immune response studies are being launched at Harvard and at Duke to explore that possibility."

About Los Alamos National Laboratory (www.lanl.gov)

Los Alamos National Laboratory, a multidisciplinary research institution engaged in strategic science on behalf of national security, is operated by Los Alamos National Security, LLC, a team composed of Bechtel National, the University of California, The Babcock & Wilcox Company, and URS for the Department of Energy's National Nuclear Security Administration.

Los Alamos enhances national security by ensuring the safety and reliability of the U.S. nuclear stockpile, developing technologies to reduce threats from weapons of mass destruction, and solving problems related to energy, environment, infrastructure, health, and global security concerns.

SOURCE Los Alamos National Laboratory

Back to top

RELATED LINKS
http://www.lanl.gov

'/>"/>

SOURCE Los Alamos National Laboratory
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
6. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
7. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
8. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
9. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
10. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
11. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
Breaking Medicine News(10 mins):